Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart Inc (NQ: VXRT )

0.8893 -0.1007 (-10.17%)
Streaming Delayed Price Updated: 3:39 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart Inc

< Previous 1 2 3 4 5 6 7 8 Next >
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today
VXRT stock is on the move as the company received some very bullish coverage from an analyst initiating coverage today. 
Via InvestorPlace
Why Vaxart Shares Are Trading Higher Today
Vaxart Inc (NASDAQ:VXRT) shares are trading higher by 30% ... 
Via Benzinga
Most Active Equity Options For Midday - Friday, June 11
Top tickers for midday: AMC, AAPL, TSLA, NIO, NVDA, AMZN, CLOV, SNAP, CLF, GME, PLTR, VXRT, AMD, MO, F, SENS, BAC, MSFT, BB, ET. 
Via Talk Markets
Nasdaq, S&P 500 Eye Weekly Wins as Bond Yields Retreat
The 10-year Treasury bond yield fell to a three-month low. 
Via Talk Markets
Topics Bonds Stocks
Exposures Debt Markets US Equities
46 Stocks Moving In Friday's Mid-Day Session
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,... 
Via Benzinga
Why Vaxart Stock Is Skyrocketing Today
Investors are cheering an analyst's positive recommendation. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
Why Shares of Vaxart Plummeted 38.6% in May
This isn't the first time its coronavirus vaccine pill has disappointed investors. 
Via The Motley Fool
Exposures COVID-19
Bet on a No-Needle Vaccine Strategy with Vaxart
Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment. 
Via InvestorPlace
Exposures COVID-19
10 More Current & Former Penny Stocks With High Short Interest
High Short Interest Stocks Are Something Traders Are On The Hunt For & Here's Another 10 
Via Talk Markets
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aytu Biopharma, Inc. (NASDAQ: AYTU) rose 37.8% to $7.40 in pre-market trading. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) rose 23.5% to $3.89 in pre-market trading... 
Via Benzinga
5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street
If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year. 
Via The Motley Fool
Topics Economy
Exposures Economy
These Vaccine Latecomers Could Still Win Big. Here's How
The key is standing out from the crowd. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Vaxart’s Compelling Story Will Take a Long Time to Play Out
As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off. 
Via InvestorPlace
Exposures COVID-19
With Fading Covid-19 Infections, Vaxart’s Relevance Is Waning
Prior to the vaccination rollout from Vaxart’s competitors, VXRT stock appeared a compelling alternative. That’s no longer the case. 
Via InvestorPlace
Exposures COVID-19
Speculators Should Consider Buying Vaxart Stock
Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. 
Via InvestorPlace
Exposures COVID-19
Vaxart Could Still Be a Viable Covid 19 Vaccine Play
VXRT stock needs to nail the next few studies of its Covid-19 vaccine candidate and prove its thesis to strengthen its bull case. 
Via InvestorPlace
Exposures COVID-19
Ocugen or Vaxart: Which Will Take Investors Further?
These two high-flying biotechs are vying for the same market. 
Via The Motley Fool
Exposures COVID-19
High Cash Burn Will Push Vaxart Stock Down To $1 Per Share
Failed clinical trials and high cash burn mean Vaxart is headed down to cash per share levels. That suggests VXRT stock is worth just $1. 
Via InvestorPlace
Exposures COVID-19
It Won’t Take Much for Vaxart Stock to Pop Once Again
Vaccine stocks are risky, but Americans nervous about a shot might make the difference for VXRT stock 
Via InvestorPlace
Exposures COVID-19
Is Vaxart a Buy?
Can this troubled coronavirus vaccine developer redeem itself and its investors? 
Via The Motley Fool
Exposures COVID-19
Vaxart’s No-Shot Vaccine Is a Potential Game Changer
VXRT stock is down from its highs, but there's no need to worry, as Vaxart has a unique Covid-19 vaccine and some encouraging clinical data. 
Via InvestorPlace
Exposures COVID-19
Is Vaccine Maker Vaxart Worth Holding From Here?
As with most investment decisions, whether to hold depends on the situation. Here are some things to think about. 
Via The Motley Fool
Exposures COVID-19
Better Vaccine Stock: Ocugen or Vaxart?
Here's how the biotechs compare on several key fronts. 
Via The Motley Fool
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the Association for Research in Vision and Ophthalmology... 
Via Benzinga
30 Stocks Moving in Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares rose 94.2% to $2.33 in pre-market trading. Stealth BioTherapeutics showcased data for Elamipretide in dry age-related... 
Via Benzinga
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?
If it can reach the market of people that are hesitant to be vaccinated, yes. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.